Business Wire

VA-CVENT

3.10.2018 13:02:12 CEST | Business Wire | Press release

Share
Cvent Expands Partnership with AccorHotels

Cvent , a market leader in meetings, events, and hospitality technology, today announced that renowned brand and long-time Cvent customer AccorHotels will utilize Cvent’s Business Transient solutions exclusively across their more than 4,500 hotels worldwide to more effectively manage their corporate travel programs. The announcement highlights AccorHotels’ continued commitment to their hotel partners to help them grow revenue and increase market share through Cvent’s industry-leading software solutions. Additionally, the two brands will collaborate on the creation of new technology that will help hospitality professionals worldwide better manage their travel programs.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181003005210/en/

“Eighty percent of Fortune 100 companies use Cvent technology, and more than 1.5 million RFPs were sourced through Cvent’s Business Transient platform in the last year, which indicates its indispensable role for both buyers and sellers in the corporate travel market. Properties that are able to fully leverage the platform to help them attract corporate buyers with smarter marketing solutions will ultimately generate more booked room nights,” said Kathleen Garcia, Vice President of Sales for Cvent’s Hospitality Cloud. “AccorHotels, one of Europe’s most recognized hospitality brands, has embraced this opportunity to grow their corporate travel programs across their thousands of hotels, and we are proud to be their exclusive business travel management solution. We look forward to supporting their continued success and working as a trusted partner to help them grow their MICE and corporate travel business worldwide.”

AccorHotels and their thousands of properties worldwide will gain access to Cvent’s complete suite of Business Transient tools to help them address their travel management needs. The solutions will help the properties better manage their RFP process, market to corporate travel buyers, and improve operational efficiency, facilitating future business transient growth. AccorHotels’ use of Cvent highlights the opportunity for leading hospitality brands to better manage their business travel needs.

Cvent and AccorHotels will also work together on the co-development of additional travel management capabilities that will focus on expanding transient sourcing features, creating the tools to give properties a more holistic view of rates across all market segments, and streamlining manual processes through deeper system integrations.

“We have worked with Cvent for 10 years and our properties have been very satisfied with the seamless workflow of Cvent tools both on MICE and corporate travel business,” said Agathe Fabron AccorHotels VP Business Travel & Meetings & Events. “Many of our properties have been using Cvent Business Transient for their travel needs and the positive impact we have seen thus far made the decision to roll it out worldwide very easy. We look forward to continuing this long-standing relationship and to work hand-in-hand with the Cvent team to drive our corporate travel business, and the industry, forward.”

About Cvent, Inc.

Cvent, Inc. is a leading meetings, events, and hospitality management technology provider with more than 3,500 employees, 25,000 customers, and 300,000 users worldwide. The Cvent Event Cloud offers software solutions to event planners for online event registration, venue selection, event management, mobile apps for events, email marketing, and web surveys. The Cvent Hospitality Cloud partners with hotels and venues to help them drive group/MICE and corporate travel business. Hotels use the Cvent Hospitality Cloud’s digital marketing tools and software solutions to win business through Cvent’s sourcing platforms and to service their customers directly, efficiently and profitably – helping them grow and own their business. Cvent solutions optimize the entire event management value chain and have enabled clients around the world to manage hundreds of thousands of meetings and events. For more information, please visit Cvent.com , or connect with us on FacebookTwitter  or LinkedIn .

About AccorHotels

AccorHotels is a world-leading travel & lifestyle group and digital innovator offering unique experiences in more than 4,500 hotels, resorts and residences across 100 different countries. With an unrivaled portfolio of internationally renowned hotel brands encompassing the entire range from luxury to economy, from upscale to lifestyle and midscale brands, AccorHotels has been providing savoir-faire and expertise for more than 50 years.

In addition to its core hospitality business, AccorHotels has successfully expanded its range of services, becoming the world leader in luxury private residence rental with more than 10,000 stunning properties around the world. The Group is also active in the fields of concierge services, co-working, dining, events management and digital solutions.

Relying on its global team of more than 250,000 dedicated staff, AccorHotels is committed to fulfilling its primary mission: to make every guest Feel Welcome. Guests have access to one of the world’s most attractive hotel loyalty programs - Le Club AccorHotels.

For more information or to make a reservation, please visit accorhotels.group or accorhotels.com. Or join and follow us on Twitter and Facebook.

Contact:

Cvent, Inc. Erica Stoltenberg 571-378-6240 estoltenberg@cvent.com or Spotl1ght Communications Sam Pepper sam.pepper@spotlightcoms.com or Sharon Coleshill +44 (0) 208 334 4005 sharon.coleshill@spotlightcoms.com

Link:

ClickThru

Social Media:

https://www.facebook.com/Cvent/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release

SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye